AstraZeneca Announces Truqap Combination Approved In The U.S. As First And Only Targeted Treatment For PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

뉴스 본문을 불러오고 있어요.

AstraZeneca Announces Truqap Combination Approved In The U.S. As First And Only Targeted Treatment For PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer | 웨이프 WAPE

AstraZeneca Announces Truqap Combination Approved In The U.S. As First And Only Targeted Treatment For PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

기사 요약

관련 종목

댓글 —